Kidney Cancer Profile in National Cancer Center (NCC) - Dharmais Cancer Hospital
Abstract
Background: Kidney cancer is one of the most prevalent cancers in urology. The higher prevalence of risk factors, as well as better diagnostic modalities, has led to a reported increase worldwide. The study aims to describe the profile and management pattern of kidney cancer patients at a tertiary referral center over seven years.
Methods: A descriptive study was conducted to assess the profile and management of kidney patients in the national cancer center (NCC) - Dharmais Hospital Jakarta between January 2013 and December 2020. The variables collected included age, gender, stage (AJCC staging), histopathological result, and management, using the total sampling method.
Results: A total of 53 kidney cancer cases were documented in NCC - Dharmais Hospital Jakarta from 2013 to 2020. Overall, males are more prevalent than females, with a sex ratio of 2.3:1. The most frequent age group was 51–65 years. The most common histological subtype was a clear cell in the renal cell carcinoma (RCC) subtype and sarcoma in the non-RCC subtype. Noticeably, end-stage (stage IV) was found in more than half of patients (65.6%), with no patient found in stage I. Radical nephrectomy was preferable to cytoreductive nephrectomy.
Conclusions: : An increasing trend of kidney cancer incidence was found between 2013 and 2020 with most patients diagnosed with stage IV.
Keywords
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Patel AR, Prasad SM, Shih YC, et al. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012;187(6):1978-83.
Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-30.
Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245-57.
Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79-87.
Hamid A, Umbas R, Oka A, et al. [Guidelines for the Management of Kidney Cancer]. 2nd ed. Jakarta: Ikatan Ahli Urologi Indonesia; 2020.
Chiong E, Tay MH, Tan MH, et al. Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol. 2012;13(11):e482-91.
Chevrier S, Levine JH, Zanotelli VRT, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169(4):736-49.e18.
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75(5):799-810.
Li P, Znaor A, Holcatova I, et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67(6):1134-41.
van de Schans SA, Aben KK, Mulders PF, et al. Modest improvement in 20 years of kidney cancer care in the Netherlands. Eur J Cancer. 2012;48(12):1822-30.
Marugame T, Matsuda T. Comparison of time trends in kidney cancer incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents, Vols IV-VIII. Jpn J Clin Oncol. 2008;38(7):508-9.
Chang YH, Chang SW, Liu CY, et al. Demographic characteristics and complications of open and minimally invasive surgeries for renal cell carcinoma: a population-based case-control study in Taiwan. Ther Clin Risk Manag. 2018;14:1235-41.
Saad AM, Gad MM, Al-Husseini MJ, et al. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. Clin Genitourin Cancer. 2019;17(1):46-57.e5.
Hajgude V, Umalkar R. A clinical study of patients with renal cell carcinoma. 2016. 2016;3(1):4.
Gelfond J, Al-Bayati O, Kabra A, et al. Modifiable risk factors to reduce kidney cell carcinoma incidence: Insight from the PLCO trial. Urol Oncol Semin Orig Investig. 2018;36(7):340.e1-.e6.
Mancini M, Righetto M, Baggio G. Gender-Related Approach to Kidney Cancer Management: Moving Forward. Int J Mol Sci. 2020;21(9):3378.
Zhu G, Liang L, Li L, et al. The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology. 2014;83(2):510.e19-24.
Chen Y, Sun Y, Rao Q, et al. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget. 2015;6(31):31203-15.
Huang Q, Sun Y, Ma X, et al. Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma. Nature Communications. 2017;8(1):918.
Yu C-P, Ho J-Y, Huang Y-T, et al. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation. PLoS One. 2013;8(2):e56667-e.
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74-84.
Thorstenson A, Bergman M, Scherman-Plogell AH, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014;48(3):231-8.
Öztürk H. Prognostic features of renal sarcomas (Review). Oncol Lett. 2015;9(3):1034-8.
Lalwani N, Prasad SR, Vikram R, et al. Pediatric and adult primary sarcomas of the kidney: a cross-sectional imaging review. Acta Radiol. 2011;52(4):448-57.
Wang X, Xu R, Yan L, et al. Adult renal sarcoma: clinical features and survival in a series of patients treated at a high-volume institution. Urology. 2011;77(4):836-41.
Xie W, Wei L, Guo J, et al. Physiological functions of Wilms' tumor 1-associating protein and its role in tumourigenesis. J Cell Biochem. 2019.
Varan A. Wilms' tumor in children: an overview. Nephron Clin Pract. 2008;108(2):c83-90.
Rao GK, Ramachandra M, Pradad MVD, et al. Clinical profile of kidney cell carcinoma- a retrospective descriptive study. J Evolution Med Dent Sci. 2019;8(31):2490-3.
Wang D, Xiao Z, Shou J, et al. Comparison of Laparoscopy and Open Radical Nephrectomy of Renal Cell Cancer. Open Med (Wars). 2019;14:392-7.
Xiao WJ, Zhu Y, Dai B, et al. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis. Int Braz J Urol. 2015;41(2):288-95.
Ljungberg B, Albiges L, Bensalah L, et al. EAU-ESTRO-SIOG Guidelines on Renal Cell Carcinoma. Amsterdam: Euro Urol; 2020.
DOI: 10.33371/ijoc.v16i4.904
Article Metrics
Abstract view : 142 timesPDF - 70 times
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Indonesian Journal of Cancer
Email this article 
